Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use

Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia (TM); hereafter referred to as PTAH), is the first oral immunotherapy approved in the USA and European Commission for mitigating allergic reactions in children aged 4-17 years with peanut allergy. In the pivotal phase 3 studies in patients with peanut allergy, relative to placebo, PTAH significantly desensitized to peanut protein and reduced severity of allergic reactions to accidental peanut exposure, together with improvements in food allergy-related quality of life. The clinical benefits of PTAH were maintained with continued treatment for up to 2 years. Most adverse events with PTAH, including systemic allergic reactions, were of mild to moderate severity. Frequency and severity of adverse events decreased with continued treatment. Plain Language Summary Peanut allergy is a major growing health problem worldwide. Current management of peanut allergy includes strict peanut avoidance and management of acute allergic reactions. With various routes of immunotherapy being investigated as a potential treatment option, peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia (TM); hereafter referred to as PTAH) is the first oral immunotherapy approved for children aged 4-17 years with peanut allergy. In children with peanut allergy, PTAH increased desensitization to peanut protein and reduced severity of allergic symptoms relative to placebo. Patients treated with PTAH also reported improvements in food allergy-related quality of life. Adverse events seen with PTAH, including systemic allergic reactions, are generally mild or moderate in severity. PTAH is a novel effective treatment option for mitigating allergic symptoms in children with peanut allergy.